Funded Biotechnology Startups in Australia
Disclosed round sizes in this Australia biotechnology set are led by a single outlier: Telix Pharmaceuticals’ $600M round on 2026-04-14, which dwarfs the n…
Disclosed round sizes in this Australia biotechnology set are led by a single outlier: Telix Pharmaceuticals’ $600M round on 2026-04-14, which dwarfs the next-largest disclosed amounts (e.g., Opthea at $114M on 2024-06-12 and Propanc at $100M on 2025-10-15). The rest of the disclosed rounds cluster far lower, with many entries in the low-to-mid tens of millions (such as Mesoblast $50M on 2026-06-24, Opthea $114M in June 2024, and Ena Respiratory $22M on 2025-10-22).
The list also shows stage/timing concentration and missing-data patterns. “Series Unknown” appears in 29 of 50 rows, and “undisclosed” appears in 3 of 50 (Proseek Bio 2026-04-08; Cell Bauhaus 2024-10-10; Arose 2023-03-20). City clustering is visible around Melbourne, Victoria (e.g., Fluent $2M on 2026-06-29; Mesoblast $50M on 2026-06-24; Paradigm Biopharmaceuticals $10M on 2026-04-27; RAGE Biotech $19M on 2025-11-10; Nutromics $7M on 2023-06-08), while the temporal span runs from 2022-11-03 (Tiny Bright Things, $2M) to 2026-06-29 (Fluent, $2M).
Most recent rounds
50 of 588 more funded startups
This page shows the 50 most recent rounds (back to Nov 2022). The full 58-company history for this listing is available on a paid plan.
Unlock all 58 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
Which disclosed round is the outlier, and how far above the rest are disclosed amounts in this dataset?
Telix Pharmaceuticals’ $600M round on 2026-04-14 is the only disclosed amount in this list above $100M, while the next-largest disclosed figures include Opthea at $114M (2024-06-12) and Propanc at $100M (2025-10-15). This makes Telix’s disclosed size an extreme outlier relative to the many rounds clustered in the single-digit millions up to the tens of millions (for example, BiomeBank $11M on 2026-04-17 and RAGE Biotech $19M on 2025-11-10).
Are rounds concentrated in a narrow recent time window, or spread evenly across years?
For recent activity, several rounds land in a short late-June to April 2026 window: Fluent $2M (2026-06-29), Mesoblast $50M (2026-06-24), Microba Life Sciences $4M (2026-06-12), and Telix Pharmaceuticals $600M (2026-04-14). Across the full set of 50 rows, however, dates span from 2022-11-03 (Tiny Bright Things $2M) to 2026-06-29, indicating multi-year spread rather than a single burst.
How dominant is 'Series Unknown' compared with named stages, and what’s the implication for analyst screening?
“Series Unknown” is used in 29 of 50 rows, and “undisclosed” appears in 3 of 50 (Proseek Bio on 2026-04-08; Cell Bauhaus on 2024-10-10; Arose on 2023-03-20). Practically, stage-based filtering will be constrained: named stages show up less frequently than “Series Unknown,” so comparisons by stage will rely on a subset of rows such as Seed (e.g., Fluent $2M, 2026-06-29; Levur $780K, 2025-05-06) and Series B (e.g., Ena Respiratory $22M, 2025-10-22; Proto Axiom $20M, 2024-08-12).
Which city appears most repeatedly, and does it correlate with larger or more frequent round sizes?
Melbourne, Victoria shows up repeatedly across multiple years and sizes, including Fluent $2M (2026-06-29), Mesoblast $50M (2026-06-24), Paradigm Biopharmaceuticals $10M (2026-04-27), RAGE Biotech $19M (2025-11-10), and Nutromics $7M (2023-06-08). The list also includes other cities (Sydney, Brisbane, Perth, Adelaide, and Orange), but Melbourne’s recurrence makes it the clearest geographic cluster in these 50 entries.
Do named stages reveal any pattern in typical disclosed sizes (e.g., Seed vs Series B), despite many missing stage labels?
Where stages are named, Seed rounds often sit in the sub-$10M range (e.g., Fluent $2M on 2026-06-29; Levur $780K on 2025-05-06; Earthodic $4M on 2024-10-29), while Series B and Series C include higher disclosed amounts (e.g., Ena Respiratory $22M on 2025-10-22; Proto Axiom $20M on 2024-08-12; Vaxxas $23M on 2022-12-05). That said, because 29 rows are “Series Unknown,” stage-size conclusions apply to the named subset rather than the full set of 50.
Which other large disclosed rounds (besides Telix) stand out as upper-tier events?
Outside the Telix $600M outlier, the next tier includes Opthea at $114M on 2024-06-12, Propanc at $100M on 2025-10-15, and Immutep at $60M on 2024-06-05. Several other high-single/upper tens of millions appear close behind, such as Ena Respiratory $22M (2025-10-22), OncoRes Medical $19M (2026-02-12), and Anteris Technologies $24M (2023-02-09), indicating a secondary band of larger disclosed financings even after the top outlier.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.